ReviewInternational nano letters2022
Multifarious global flora fabricated phytosynthesis of silver nanoparticles: a green nanoweapon for antiviral approach including SARS-CoV-2.
Review in International nano letters, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 13 citations in OpenAlex.
- Article
- Biosynthesis of TiOBMC chemistry · 2024Article
- From nature to nanomedicine: bioengineered metallic nanoparticles bridge the gap for medical applications.Discover nano · 2024Review
- A systematic overview of metal nanoparticles as alternative disinfectants for emerging SARS-CoV-2 variants.Archives of microbiology · 2024Review
- Biosynthesis of Copper Nanoparticles with Medicinal Plants Extracts: From Extraction Methods to Applications.Micromachines · 2023Review
- Plant Cell-Engineered Gold Nanoparticles Conjugated to Quercetin Inhibit SARS-CoV-2 and HSV-1 Entry.International journal of molecular sciences · 2023Article
- Current Trends and Prospects for Application of Green Synthesized Metal Nanoparticles in Cancer and COVID-19 Therapies.Viruses · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The progressive research into the nanoscale level upgrades the higher end modernized evolution with every field of science, engineering, and technology. Silver nanoparticles and their broader range of application from nanoelectronics to nano-drug delivery systems drive the futuristic direction of nanoengineering and technology in contemporary days. In this review, the green synthesis of silver nanoparticles is the cornerstone of interest over physical and chemical methods owing to its remarkable biocompatibility and idiosyncratic property engineering. The abundant primary and secondary plant metabolites collectively as multifarious phytochemicals which are more peculiar in the composition from root hair to aerial apex through various interspecies and intraspecies, capable of reduction, and capping with the synthesis of silver nanoparticles. Furthermore, the process by which intracellular, extracellular biological macromolecules of the microbiota reduce with the synthesis of silver nanoparticles from the precursor molecule is also discussed. Viruses are one of the predominant infectious agents that gets faster resistance to the antiviral therapies of traditional generations of medicine. We discuss the various stages of virus targeting of cells and viral target through drugs. Antiviral potential of silver nanoparticles against different classes and families of the past and their considerable candidate for up-to-the-minute need of complete addressing of the fulminant and opportunistic global pandemic of this millennium SARS-CoV2, illustrated through recent silver-based formulations under development and approval for countering the pandemic situation. Graphical abstract:
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.